Study guide
5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods
Key Takeaways Explain This Topic AI
Combined hormonal contraceptives (CHCs) prevent conception primarily by suppressing hypothalamic-pituitary gonadotropin secretion (estrogen suppresses FSH to inhibit follicle selection; progestin suppresses LH to prevent ovulation) while altering cervical mucus and the endometrium.
Estrogen components include ethinyl estradiol (10–35 mcg), estetrol (E4, fetal liver-derived native estrogen with tissue selectivity), and estradiol valerate; progestins are categorized into four generations with varying androgenic, antiandrogenic, and antimineralocorticoid potencies.
The norelgestromin/ethinyl estradiol transdermal patch delivers steady-state systemic estrogen exposure (AUC up to 60% higher than 35 mcg COCs) and its labeling contraindicates use at a BMI of 30 kg/m² or higher (VTE risk) and warns of lower efficacy at 90 kg or more.
Progestin-only pills (POPs) range from traditional norethindrone (0.35 mg, strict 3-hour missed pill window, primary mechanism of cervical mucus thickening) to drospirenone (4 mg 24/4 regimen, 24-hour missed pill window, consistent ovulation suppression).
Depot medroxyprogesterone acetate (DMPA, 150 mg IM or 104 mg SubQ every 13 weeks) induces profound anovulation and amenorrhea (50–70% at 1 year) but carries a Black Box warning for reversible bone mineral density loss and a median 9- to 10-month return-to-fertility delay.
Last updated: October 2026
Mechanisms of Combined Hormonal Contraceptives (CHCs)
Combined hormonal contraceptives (CHCs)—oral pills, transdermal patches, and vaginal rings—contain an estrogen and a progestin component that act synergistically to inhibit conception via negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis:
Estrogen Component (FSH Suppression): Suppresses pituitary secretion of follicle-stimulating hormone (FSH), preventing dominant ovarian follicle recruitment and selection. Estrogen also stabilizes the endometrial vascular architecture to minimize unscheduled breakthrough bleeding.
Progestin Component (LH Suppression & Peripheral Hostility): Suppresses the mid-cycle luteinizing hormone (LH) surge from the anterior pituitary, reliably inhibiting ovulation. Progestins also induce peripheral contraceptive barriers: thickening cervical mucus within hours into a viscid, sperm-impenetrable plug, altering fallopian tubal ciliary transit, and inducing endometrial stromal decidualization and glandular atrophy hostile to blastocyst implantation.
- Estrogen Formulations & Progestin Generations
- Estrogen Components
Ethinyl Estradiol (EE): Synthetic 17α-alkylated estradiol resistant to hepatic first-pass metabolism, with modern low-dose formulations containing 10–35 mcg. Doses ≥50 mcg are obsolete for routine contraception due to venous thromboembolism (VTE) risks.
Estradiol Valerate: Synthetic ester prodrug rapidly cleaved to 17β-estradiol, matched with dienogest in a four-phase oral regimen.
Estetrol (E4): Native estrogen produced by the human fetal liver during pregnancy. Characterized as a Native Estrogen with Selective tissue activity (NEST), E4 displays agonistic activity on bone, endometrium, and vagina, but neutral-to-antagonistic activity on breast tissue and hepatic hemostasis. Formulated with drospirenone (14.2 mg E4 / 3 mg DRSP), it exerts minimal impact on coagulation factors and lipids compared to EE.
Progestin Generations & Receptor Profiles
Progestins bind to progesterone receptors (PR) but exhibit cross-reactivity with androgen (AR) and mineralocorticoid (MR) receptors:
Generation Progestins Parent Molecule Androgenic Activity VTE Risk Profile Key Clinical Characteristics
1st Gen Norethindrone, Ethynodiol diacetate 19-Nortestosterone Mild Baseline VTE reference Shorter half-life; slightly higher unscheduled spotting.
2nd Gen Levonorgestrel, Norgestrel 19-Nortestosterone Highest Lowest relative VTE risk among CHCs High affinity for AR; may worsen acne and hirsutism; established metabolic and cardiovascular safety.
3rd Gen Desogestrel, Norgestimate 19-Nortestosterone Low to Minimal Slightly higher VTE risk vs 2nd gen Structurally modified to diminish androgenic side effects; favorable for acne and lipid profiles.
4th Gen Drospirenone Spironolactone analog Antiandrogenic Comparable/slightly higher VTE risk vs 2nd gen Spironolactone analogue; antimineralocorticoid (blocks aldosterone, reducing water retention/bloating) and antiandrogenic (clears acne); risk of hyperkalemia.
Note
Drospirenone 3 mg possesses antimineralocorticoid activity equivalent to ~25 mg of spironolactone. Check serum potassium in patients taking daily medications predisposing to hyperkalemia (ACE inhibitors, ARBs, potassium-sparing diuretics, chronic daily NSAIDs).
- Non-Oral Combined Delivery Systems
- Transdermal Contraceptive Patch
Formulation: Norelgestromin 150 mcg / ethinyl estradiol 35 mcg daily (Xulane, Zafemy) applied weekly for 3 consecutive weeks followed by 1 patch-free week; levonorgestrel / EE patch (Twirla).
Pharmacokinetics: Bypasses hepatic first-pass metabolism, providing continuous steady-state hormone levels. However, total systemic estrogen exposure (AUC) is up to 60% higher than standard 35 mcg oral COCs.
Weight & BMI Warning: Current Xulane labeling carries a boxed warning that the patch is contraindicated with BMI ≥30 kg/m² (higher VTE risk) and in smokers over 35; the label also notes it may be less effective at ≥90 kg (198 lb) . The levonorgestrel patch (Twirla) is likewise contraindicated at BMI ≥30.
Application: Apply to clean, dry skin on the buttocks, abdomen, upper arm, or torso. Application to the breasts is strictly contraindicated .
Contraceptive Vaginal Rings
Etonogestrel / EE Ring (NuvaRing, EluRyng): Releases 120 mcg etonogestrel / 15 mcg EE daily. Inserted for 3 weeks (21 days), followed by 1 ring-free week (7 days). If the ring has been out for 48 hours or longer , reinsert it and use backup contraception for 7 days; if out less than 48 hours, reinsert as soon as possible with no backup (US SPR 2024).
Segesterone Acetate / EE Ring (Annovera): Reusable silicone elastomer ring releasing 150 mcg segesterone / 13 mcg EE daily. Kept in place for 21 days, removed for 7 days (washed and stored in its case), and reinserted for a total of 13 cycles (1 full year) .
Progestin-Only Pills (POPs)
Traditional Norethindrone POP (0.35 mg): Taken daily without hormone-free intervals. Primary mechanism is cervical mucus thickening (peaks at 4 hours, wanes by 20–24 hours) and endometrial thinning; ovulation is inhibited in only ~50% of cycles. Due to this pharmacokinetics, taking a pill >3 hours late constitutes a missed dose. If late by >3 hours, take the pill immediately, resume the daily schedule, and use backup barrier contraception for 48 hours .
Norgestrel POP (Opill, 0.075 mg): Approved for over-the-counter sale in 2023; like norethindrone, it has a 3-hour window and acts mainly by thickening cervical mucus.
Drospirenone POP (Slynd, 4 mg 24/4 regimen): Deeply suppresses pituitary ovulation and thickens cervical mucus. Provides a 24-hour missed-pill window , offering the forgiveness of COCs without estrogenic thromboembolic risks.
Depot Medroxyprogesterone Acetate (DMPA)
Administered as 150 mg IM (deltoid or gluteal) or 104 mg SubQ (anterior thigh or abdomen) every 13 weeks . A 2-week grace period (up to 15 weeks) applies before pregnancy exclusion is needed.
Endocrine Effects & Bleeding: Suppresses hypothalamic GnRH pulsatility and pituitary FSH/LH secretion, abolishing ovulation. Initial unscheduled spotting resolves into amenorrhea in 50% of users at 1 year and 70% at 2 years .
Bone Mineral Density (BMD) Counseling: Hypoestrogenism causes reversible bone density reduction, most pronounced during years 1–2. The FDA Black Box warning recommends limiting use to 2 years unless other methods are inadequate; however, ACOG, CDC, and WHO consensus guidelines advise against arbitrarily restricting duration to 2 years , as bone density recovers post-discontinuation and fracture risk is not elevated. Counsel on 1,000–1,200 mg daily elemental calcium, 600–800 IU vitamin D, and weight-bearing exercise. Routine DEXA scans are not recommended.
Delayed Fertility Return: Median time to ovulation following discontinuation is 9 to 10 months , extending up to 18 months.